000028 China National Accord Medicines Corporation
- 32.50
- +2.03+6.66%
China National Accord Medicines Corporation News
Sinopharm is consistent: 2024 semi-annual financial report
Sinopharm Consistent: Semi-Annual Financial Report
Sinopharm is consistent: a summary table of non-operating capital usage and other related capital transactions for the half year
China National Accord Medicines Corporation: Company bylaws (revised June 2024).
China National Accord Medicines Corporation: Announcement of resolution of the Second Extraordinary Shareholders' Meeting in 2024.
China National Accord Medicines Corporation: Announcement Regarding the Election of Worker Representatives for the Tenth Supervisory Board
China National Accord Medicines Corporation: Legal opinion for the second extraordinary shareholders' meeting in 2024.
China National Accord Medicines Corporation: Company bylaws (revised June 2024).
China National Accord Medicines Corporation: Notice Regarding the Holding of the Second Extraordinary Shareholders' Meeting in 2024.
China National Accord Medicines Corporation: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
China National Accord Medicines Corporation: Legal Opinions of the 2023 Annual General Meeting of Shareholders
Sinopharm agrees: Announcement on additional provisional proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice of the Shareholders\' Meeting
Sinopharm's agreement: announcement on the resignation of a director
Sinopharm is consistent: 2023 annual financial report
Sinopharm agrees: the company\'s 2023 special report on financial services related to financial companies
Sinopharm agrees: financial services agreement with finance companies
Sinopharm\'s agreement: Notice of the annual shareholders\' meeting
Sinopharm agrees: shareholder return plan for the next three years (2024-2026)
Sinopharm agreement: Announcement on the signing of a financial service agreement and related transactions between the company and Sinopharm Group Finance Co., Ltd.
Sinopharm is consistent: internal control self-evaluation report
Analysis
Price Target
No Data
No Data